Stockscreener 앱 받기
4.60
4.17%
-0.20
전일 마감가:
$4.80
열려 있는:
$5
하루 거래량:
1.89M
Relative Volume:
1.10
시가총액:
$411.08M
수익:
-
순이익/손실:
$-29.07M
주가수익비율:
-15.86
EPS:
-0.29
순현금흐름:
$-31.85M
1주 성능:
+13.02%
1개월 성능:
+29.40%
6개월 성능:
+63.70%
1년 성능:
+73.58%
1일 변동 폭
$4.55
$5.05
1주일 범위
$3.9625
$5.05
52주 변동 폭
$2.30
$5.05
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
TRVI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
4.60 | 411.08M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Oppenheimer Adjusts Trevi Therapeutics Price Target to $12 From $9, Maintains Outperform Rating - Marketscreener.com
Trevi Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Why Trevi Therapeutics (TRVI) Is Advancing Today - Insider Monkey
Trevi Therapeutics stock soars to 52-week high of $4.68 - Investing.com
FY2029 Earnings Estimate for TRVI Issued By B. Riley - Defense World
Contrasting Phibro Animal Health (NASDAQ:PAHC) & Trevi Therapeutics (NASDAQ:TRVI) - Defense World
SG Americas Securities LLC Acquires 3,387 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
President & CEO GOOD JENNIFER L sale 4,219 shares of Trevi Therapeutics Inc [TRVI] - Knox Daily
A closer look at Trevi Therapeutics Inc (TRVI)’s stock price trends - US Post News
Trevi Therapeutics Inc (TRVI) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update - MarketBeat
JPMorgan Chase & Co. Buys 69,167 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
JPMorgan Chase & Co. Has $336,000 Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Certain Common Stock Warrants: of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 31-JAN-2025. - Marketscreener.com
Certain Pre-funded Warrants of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 31-JAN-2025. - Marketscreener.com
Certain Stock Options of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 31-JAN-2025. - Marketscreener.com
Chronic Refractory Cough Pipeline 2024: In-depth Clinical - openPR
Trevi Therapeutics to Participate in Upcoming February Investor Conferences – Company Announcement - Financial Times
Trevi Therapeutics to Participate in Upcoming February Investor Conferences - PR Newswire
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.31 Consensus Target Price from Brokerages - Defense World
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $9.31 - MarketBeat
FY2024 Earnings Forecast for TRVI Issued By Leerink Partnrs - Defense World
What is Leerink Partnrs' Forecast for TRVI FY2024 Earnings? - MarketBeat
Trevi Therapeutics Announces Abstract Presentation at the Americ - GuruFocus.com
Barclays PLC Acquires 61,317 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Short Interest in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Decreases By 17.0% - MarketBeat
Jane Street Group LLC Sells 33,439 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Trevi Therapeutics’ $50 Million Common Stock Offering - Global Legal Chronicle
Trevi Therapeutics stock target lifted, holds Buy on treatment progress By Investing.com - Investing.com Canada
What Makes Trevi Therapeutics (TRVI) a New Buy Stock - Yahoo Finance
Trevi Therapeutics (NASDAQ:TRVI) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference - Nasdaq
Trevi Therapeutics (TRVI) Stock Price, News & Analysis - MarketBeat
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GuruFocus.com
Geode Capital Management LLC Increases Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
Geode Capital Management LLC Has $4.22 Million Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Barclays PLC Raises Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics stock soars to 52-week high of $4.68 By Investing.com - Investing.com Australia
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a - GuruFocus.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
State Street Corp Has $3.18 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Retail Chatter For Trevi Therapeutics Soars After Enrollment Target For Chronic Cough Study Hits 75% - MSN
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Large Increase in Short Interest - MarketBeat
Trevi Therapeutics Reports Second Quarter 2024 Financial Results - GuruFocus.com
BNP Paribas Financial Markets Purchases 6,764 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
트레비 테라퓨틱스 주식 (TRVI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Delfini Lisa | Chief Financial Officer |
Jan 07 '25 |
Option Exercise |
0.51 |
1,000 |
511 |
59,660 |
| Galletta Christopher | See Remarks |
Dec 13 '24 |
Option Exercise |
0.51 |
15,000 |
7,665 |
19,935 |
| GOOD JENNIFER L | President & CEO |
Sep 06 '24 |
Option Exercise |
1.43 |
4,219 |
6,033 |
217,532 |
| GOOD JENNIFER L | President & CEO |
Sep 09 '24 |
Option Exercise |
1.43 |
1,840 |
2,631 |
215,153 |
| GOOD JENNIFER L | President & CEO |
Sep 06 '24 |
Sale |
3.03 |
4,219 |
12,784 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 09 '24 |
Sale |
3.04 |
1,840 |
5,587 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 05 '24 |
Option Exercise |
1.43 |
40,277 |
57,596 |
253,590 |
| GOOD JENNIFER L | President & CEO |
Sep 04 '24 |
Option Exercise |
1.43 |
10,981 |
15,703 |
224,294 |
| GOOD JENNIFER L | President & CEO |
Sep 03 '24 |
Option Exercise |
1.43 |
3,863 |
5,524 |
217,176 |
| GOOD JENNIFER L | President & CEO |
Sep 05 '24 |
Sale |
3.11 |
40,277 |
125,310 |
213,313 |
0.27%
3.05%
자본화:
|
볼륨(24시간):